Opinion
Congress Can't Wait—Reform Pharmacy Benefit Managers and Deliver Lower-Cost Drugs for Patients | Opinion
The PBM system intentionally blocks lower-cost, FDA-approved biosimilars from being available to patients. Biosimilars are the commonsense, bipartisan solution to out-of-control prescription drug ...